AI Protein Structure Prediction Global Market Report 2026

The artificial intelligence (AI) protein structure prediction market size has grown exponentially in recent years. It will grow from $1.8 billion in 2025 to $2.33 billion in 2026 at a compound annual growth rate (CAGR) of 29.6%. The growth in the historic period can be attributed to growth of genomic and proteomic research, adoption of AI-based bioinformatics tools, increasing drug discovery initiatives, rising computational biology applications, expansion of academic and research institutes.

The artificial intelligence (AI) protein structure prediction market size is expected to see exponential growth in the next few years. It will grow to $6.62 billion in 2030 at a compound annual growth rate (CAGR) of 29.8%. The growth in the forecast period can be attributed to growing demand for personalized medicine solutions, increasing integration of cloud and hybrid infrastructure, rising focus on AI-driven disease diagnosis, expansion of biotechnology and pharmaceutical R&D, adoption of high-throughput protein analysis platforms. Major trends in the forecast period include increasing adoption of cloud-connected protein prediction platforms, rising demand for high-performance computing systems, growing integration of molecular modeling and simulation software, expansion of bioinformatics workflow and data management solutions, rising focus on consulting, implementation, and managed services.

The growing demand for precision medicine is projected to accelerate the expansion of the AI protein structure prediction market in the coming years. Precision medicine emphasizes customizing disease prevention and treatment based on an individual’s genetic makeup, environmental influences, and lifestyle characteristics. Its increasing adoption is supported by advancements in genomic technologies that allow the identification of disease-associated molecular targets and patient-specific genetic variations. As precision medicine increasingly depends on structure-based drug discovery and molecular-level understanding, AI protein structure prediction solutions play a vital role by swiftly determining the three-dimensional configurations of therapeutically significant proteins and evaluating the effects of genetic variations on protein functionality. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, in 2023 the US Food and Drug Administration approved 16 new personalized therapies for patients with rare diseases, compared to six in 2022. Therefore, the growing demand for precision medicine is driving the expansion of the AI protein structure prediction market.

Leading companies operating in the artificial intelligence protein structure prediction market are concentrating on developing innovative solutions such as structure-based computational biology platforms to accelerate drug discovery, enable precise protein modeling, and strengthen target identification through advanced molecular simulations and AI-driven structural analysis. A structure-based computational biology platform refers to a digital system that utilizes three-dimensional protein structure data, molecular modeling techniques, and simulation algorithms to evaluate biomolecular interactions and support rational drug design and target validation. For example, in March 2024, Basecamp Research, a UK-based AI company, introduced BaseFold as a deep learning model that significantly advances 3D protein structure prediction for large and complex proteins. By enhancing AlphaFold2 with its proprietary BaseGraph dataset derived from global biodiversity sources, it achieves up to six-fold higher accuracy and three-fold improved small molecule docking performance. This breakthrough accelerates AI-driven drug discovery by enabling highly accurate modeling of challenging protein structures that were previously underrepresented in publicly available data.

In January 2026, Insitro Inc., a US-based biotechnology company, acquired CombinAbleAI Ltd. for an undisclosed amount. Through this acquisition, Insitro plans to strengthen its AI-driven drug discovery platform by incorporating CombinAbleAI’s sophisticated combinatorial biology and machine learning capabilities, allowing more effective identification of therapeutic candidates and faster drug development processes. CombinAbleAI Ltd. is an Israel-based biotechnology company specializing in AI-powered combinatorial biology solutions for drug discovery.

Major companies operating in the artificial intelligence (AI) protein structure prediction market are Schrödinger Inc., XtalPi Inc., Generate:Biomedicines Inc., Isomorphic Labs Limited, Recursion Pharmaceuticals Inc., Relay Therapeutics Inc., Arzeda Inc., BigHat Biosciences Inc., Levitate Bio Inc., Terray Therapeutics Inc., PostEra Inc., ProteinQure Inc., Genesis Therapeutics Inc., Profluent Bio Inc., Insitro Inc., Absci Corporation, Cyrus Biotechnology Inc., Cloud Pharmaceuticals Inc., Iambic Therapeutics Inc., Insilico Medicine Inc., Latent Labs, and Neoncorte Bio Inc.

North America was the largest region in the artificial intelligence (AI) protein structure prediction market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence (AI) protein structure prediction market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the artificial intelligence (AI) protein structure prediction market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The artificial intelligence (AI) protein structure prediction market consists of revenues earned by entities by providing services such as 3D protein structure modeling, structure-based drug design support, and mutation impact analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. The artificial intelligence (AI) protein structure prediction market also includes sales of protein-ligand interaction models, structure-based drug design tools, and predicted 3D protein structures. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Artificial Intelligence (AI) protein structure prediction refers to the use of AI algorithms and machine learning models to forecast the three-dimensional structures of proteins from their amino acid sequences, enabling faster and more precise insights into protein folding and function. It employs computational methods to model protein structures, which is essential for drug discovery, enzyme design, and understanding disease mechanisms.

The primary components of artificial intelligence (AI) protein structure prediction include software, hardware, and services. Software platforms use AI algorithms to analyze protein sequences and predict three-dimensional structures with high accuracy. Deployment occurs via on-premises systems, hybrid infrastructure, and cloud-connected hardware platforms, adopted by large enterprises and small and medium-sized enterprises. Applications include drug discovery, disease diagnosis, personalized medicine, academic research, biotechnology, and other fields, serving end users such as pharmaceutical and biotechnology companies, academic and research institutes, healthcare providers, and other sectors.

Tariffs on imported high-performance computing hardware, GPUs, and specialized bioinformatics workstations are impacting the AI protein structure prediction market by increasing procurement and operational costs, particularly affecting cloud-connected platforms and hardware-intensive applications. Regions such as North America, Europe, and Asia-Pacific, which rely on imported computing components, are most affected. While tariffs elevate costs, they encourage domestic manufacturing, foster local innovation in cost-efficient computational solutions, and support the development of regional bioinformatics infrastructure, providing long-term growth opportunities.

The artificial intelligence (AI) protein structure prediction market research report is one of a series of new reports that provides artificial intelligence (AI) protein structure prediction market statistics, including artificial intelligence (AI) protein structure prediction industry global market size, regional shares, competitors with a artificial intelligence (AI) protein structure prediction market share, detailed artificial intelligence (AI) protein structure prediction market segments, market trends and opportunities, and any further data you may need to thrive in the artificial intelligence (AI) protein structure prediction industry. This artificial intelligence (AI) protein structure prediction market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.